US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment-February 2024-www.financetom.com

US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment

Dec 20, 2024 1:22 PM

Dec 20 (Reuters) - The U.S. Food and Drug Administration

has approved Vertex Pharmaceuticals' ( VRTX ) next-generation

treatment for a rare and progressive genetic disease, the

company said on Friday, expanding its dominance in the market

for cystic fibrosis.

Previous page： Shift4 Payments Q3 Adjusted Earnings, Revenue Rise Next page： Replimune Q2 net loss widens

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Shift4 Payments Q3 Adjusted Earnings, Revenue Rise

Nov 6, 2025

08:15 AM EST, 11/06/2025 (MT Newswires) -- Shift4 Payments ( FOUR ) reported Q3 adjusted earnings Thursday of $1.47 per share, up from $1.39 a year earlier. Analysts surveyed by FactSet expected $1.44. Revenue for the quarter ended Sept. 30 was $1.18 billion, up from $909.2 million a year earlier. Analysts polled by FactSet expected $1.18 billion. The company's shares...

Replimune Q2 net loss widens

Nov 6, 2025

Overview * Replimune ( REPL ) fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last year * Cash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025 Outlook * Replimune ( REPL ) expects FDA decision on RP1 BLA by April 2026 * Company plans to fund operations into late 2026 Result Drivers...

BlackRock TCP Capital Q3 net investment income $0.32/share exceeds dividends

Nov 6, 2025

Overview * BlackRock TCP Capital ( TCPC ) Q3 net investment income $0.32/share, exceeding dividend payments * Net asset value per share unchanged at $8.71 from previous quarter * Company declares Q4 dividend of $0.25/share, payable December 31, 2025 Outlook * Company anticipates a $0.15 per share impact on Q4 NAV due to Renovo write-down * BlackRock TCP Capital (...

Skyline Announces Change in Strategy, New Management and First Acquisition in Critical Minerals Space

Nov 6, 2025

Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) -- - Appoints Paul Mann Executive Chairman to Lead New Strategic Direction for the Company - Company makes first Acquisition in Critical Minerals Space Hong Kong, November 6, 2025 (GLOBE NEWSWIRE) – Skyline Builders Group Holding Limited ( SKBL ) , a Cayman Islands exempted company (the “Company”), today announced a...